Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224015 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 684
- Enrollment target
NCT01224015 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 684 participants.
The verdict
NCT01224015, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 684 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
Interventions
- DRUG normal saline
- BIOLOGICAL onabotulinumtoxinA 24 U
- BIOLOGICAL onabotulinumtoxinA 44 U
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224015
The ClinicalTrials.gov registry entry for NCT01224015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which normal saline is the first listed.
NCT01224015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01224015 about?
NCT01224015 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines". This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
What is the current status of trial NCT01224015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2011-05. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01224015?
The interventions under investigation include: normal saline (DRUG), onabotulinumtoxinA 24 U (BIOLOGICAL), onabotulinumtoxinA 44 U (BIOLOGICAL).
Who is sponsoring clinical trial NCT01224015?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.